Sight Sciences, Inc. (NASDAQ:SGHT) Director Staffan Encrantz Acquires 126,664 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) Director Staffan Encrantz acquired 126,664 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was purchased at an average price of $2.19 per share, for a total transaction of $277,394.16. Following the acquisition, the director now directly owns 157,499 shares in the company, valued at approximately $344,922.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Staffan Encrantz also recently made the following trade(s):

• On Tuesday, November 14th, Staffan Encrantz bought 3,462 shares of Sight Sciences stock. The stock was purchased at an average cost of $2.00 per share, with a total value of $6,924.00.

Sight Sciences Price Performance

Sight Sciences stock opened at $2.28 on Tuesday. The company has a current ratio of 12.11, a quick ratio of 11.47 and a debt-to-equity ratio of 0.27. The company has a fifty day simple moving average of $2.92 and a 200-day simple moving average of $6.28. The stock has a market cap of $111.15 million, a P/E ratio of -1.80 and a beta of 1.52. Sight Sciences, Inc. has a 12-month low of $1.04 and a 12-month high of $15.30.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SGHT. William Blair lowered shares of Sight Sciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 12th. Piper Sandler cut shares of Sight Sciences from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $15.00 to $5.50 in a research report on Monday, September 11th. Stifel Nicolaus cut their price objective on Sight Sciences from $11.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, September 18th. Citigroup decreased their target price on Sight Sciences from $8.00 to $4.00 and set a “neutral” rating for the company in a report on Friday, September 15th. Finally, Bank of America downgraded Sight Sciences from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $10.00 to $4.50 in a report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $4.40.

Institutional Trading of Sight Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of SGHT. Mine & Arao Wealth Creation & Management LLC. acquired a new position in shares of Sight Sciences during the 1st quarter worth about $33,000. Cubist Systematic Strategies LLC purchased a new stake in Sight Sciences during the third quarter worth approximately $37,000. FMR LLC boosted its holdings in Sight Sciences by 484.6% in the second quarter. FMR LLC now owns 4,864 shares of the company’s stock valued at $44,000 after purchasing an additional 4,032 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Sight Sciences in the fourth quarter valued at approximately $54,000. Finally, Citigroup Inc. raised its holdings in Sight Sciences by 363.9% during the second quarter. Citigroup Inc. now owns 7,942 shares of the company’s stock worth $66,000 after purchasing an additional 6,230 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors and hedge funds.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.